A5030231894- Heart Failure Treatment and Management
- Potassium and Related Disorders
- Protease and Inhibitor Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Statistical Methods in Clinical Trials
- Ethics in Clinical Research
- Atherosclerosis and Cardiovascular Diseases
- Cardiac pacing and defibrillation studies
- Ion channel regulation and function
- Heart Rate Variability and Autonomic Control
- Epilepsy research and treatment
- Acute Myocardial Infarction Research
- Sphingolipid Metabolism and Signaling
- Pharmaceutical Practices and Patient Outcomes
- Cardiovascular Syncope and Autonomic Disorders
- Biosimilars and Bioanalytical Methods
- Blood Coagulation and Thrombosis Mechanisms
Bristol-Myers Squibb (United States)
2022-2024
Amgen (United States)
2018
Henry Ford Hospital
2017
Tufts Medical Center
2017
Advances in the technologies to enable patient-centric sampling (PCS) have potential improve blood sample collection by enabling clinical trial participants collect samples via self-collection or with help of a caregiver their home. Typically, assess pharmacokinetics and pharmacodynamics drug during development are collected at site venous draw. In this position paper International Consortium for Innovation Quality Pharmaceutical Development (IQ), value PCS can bring patients, datasets...
BMS-986141 is a novel potent highly selective antagonist of PAR (protease-activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus formation in isolation and combination with factor Xa inhibition high shear conditions healthy people. We sought determine whether had additive antithrombotic effects patients coronary artery disease who were receiving antiplatelet therapy.
Evaluating cardiovascular safety of sphingosine 1-phosphate (S1P) receptor modulators is warranted due to S1P expression on cardiomyocytes and vascular endothelial cells. This analysis reports the ozanimod, an modulator, in patients with moderately severely active ulcerative colitis from phase 3 True North (TN) open-label extension (OLE).
The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines importance of research to develop novel therapeutics this disorder. This can only be accomplished successful translation basic science discoveries into direct human application through effective clinical trial design execution that results in a substantially improved course outcomes. In respect, phase II trials play pivotal role determining which multitude potential should move large...
Heart failure is a burdensome cardiovascular condition associated with high rates of morbidity and mortality. The 3-month period after hospitalization vulnerable phase in which patients are at risk for mortality rehospitalization. To reduce during this period, heart reduced ejection fraction should receive guideline-directed pharmacological therapies—the right drugs the doses—before hospital discharge. Optimal pharmacotherapies these include agents that suppress renin-angiotensin-aldosterone...
Background: BMS-986141 is a novel potent highly selective antagonist of protease-activated receptor type 4 (PAR4). PAR4 antagonism has been demonstrated to reduce thrombus formation in isolation and combination with factor Xa inhibition high shear conditions healthy people. Aim: To determine whether had additive antithrombotic effects patients coronary artery disease who were receiving antiplatelet therapy. Methods: Forty-five stable heart ten volunteers completed phase 2a open-label...
In patients with heart failure (HF) who respond inadequately to loop diuretic therapy, BMS‐986308, an oral, selective, reversible renal outer medullary potassium channel (ROMK) inhibitor may represent effective a novel mechanism of action. We present data from the first‐in‐human study aimed assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following single ascending doses BMS‐986308 in healthy adult participants. Forty participants, aged 20 55 years, body mass...
Introduction: Persistent congestion and edema remain an unmet need in heart failure (HF). BMS-986308, a novel inhibitor of the Renal Outer Medullary Potassium Channel (ROMK), is predicted to enhance potassium-sparring diuresis natriuresis HF patients with persistent despite SOC treatment. We present pharmacodynamics biomarkers kidney function injury from first-in-human study BMS-986308 (NCT04763226). Method: Thirty-two adult healthy participants were assigned 1 4 dose cohorts (3, 10, 30, 100...